Roivant Sciences Ltd Ordinary Shares ROIV 深 沪
等待开盘 10-30 09:30:00 美东时间
18.76
+0.350
+1.90%
华盛通- 最 高18.91
- 今 开18.36
- 成交量 739.82万股
- 最 低 18.32
- 昨 收 18.41
- 总市值 128.13亿
- 52周最高 18.955
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 8.73
- 委 比 -68.99%
- 总股本 6.83亿
- 历史最高 18.955
- 量 比 0.91
- 振 幅 3.20%
- 历史最低 2.52
- 每 手 1
- 风险率 1.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Thermo Fisher to buy Clario for ~$8.9B plus earnouts
Thermo Fisher Scientific (NYSE:TMO) has confirmed a deal to acquire clinical trial data management firm Clario Holdings from a shareholder group led by Astorg and Nordic Capital, Novo Holding, and Cin...
10-29 18:16
Baron Health Care Fund buys ABBV, UNH, ROIV; exits WAT and COO
Baron Health Care Fund increased 5.39% in Q3 2025, compared with the 5.05% gain for the Russell 3000 Health Care Index and the 8.18% gain for the Russell 3000 Index. The fund outperformed by 9.30% on ...
10-29 02:19
Examining the Future: Neurocrine Biosciences's Earnings Outlook
Neurocrine Biosciences (NASDAQ:NBIX) is gearing up to announce its quarterly ea...
10-28 01:01
美股盘后 | AST SPACEMOBILE涨13.08%，耐克涨3.61%
AST SPACEMOBILE涨13.08%；耐克涨3.61%；Acuity Brands涨2.04%
10-01 06:12
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial
Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.
09-18 00:13
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 200 points o...
09-17 22:12
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
Roivant and Priovant announced positive results from the Phase 3 VALOR study of brepocitinib in dermatomyositis (DM). The study showed statistically significant improvements in skin and muscle disease measures, steroid-sparing effects, and rapid onset compared to placebo. At week 52, the 30 mg dose of brepocitinib achieved a mean Total Improvement Score (TIS) of 46.5 vs. 31.2 for placebo (p=0.0006). Over two-thirds of patients on 30 mg brepocitin...
09-17 11:00
Roivant Sciences Approves Proposals at Annual Meeting
An update from Roivant Sciences ( ($ROIV) ) is now available. On September 10, ...
09-12 05:29
